Investors' expectations of strong revenue performance and higher forecasted growth than the rest of the Medical Equipment industry are keeping the P/S ratio high. Shareholders' confidence in future revenues suggests the share price won't fall significantly soon.
Investors maintain STAAR Surgical's high P/E, anticipating its market outperformance. The robust earnings forecast revealed by company analysts likely contributes to its high P/E. Shareholders display confidence in future earnings, bolstering share price.
$STAAR Surgical(STAA.US)$ Many across the world have already gotten ICL implanted into their eyes to correct their Myopia. “Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again. FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
STAAR Surgical股票討論區
The best investment biotech biomed stock
2023Q1營收增長16.3%,營業利潤受費用大幅增長影響下滑77%,淨利潤下滑72%,利潤增長似乎遇到了瓶頸。
目前65倍市盈率,市盈率TTM增長到了79倍,缺乏吸引力。
Load any dips below 55
專欄Top upgrades and downgrades on 4/8
• $Afya Ltd(AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio(APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $羅賓遜物流(CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang(CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver(GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc(ITT.US)$: UBS Upgr...
專欄Today's pre-market stock movers: TSLA, AAPL, POLY and more
• $Plantronics(POLY.US)$ +50% (to be acquired by HP Inc ($惠普(HPQ.US)$) for $40.00 per share)
• $Axsome Therapeutics(AXSM.US)$ +21.6% (Jazz Pharma divests Sunosi to Axsome Therapeutics)
• $STAAR Surgical(STAA.US)$ +15.4% (receives FDA approval of EVO Visian Implantable Collamer Lenses)
• $Sarcos Technology & Robotics(STRC.US)$ +7.6% (announces that the Company has reached a definitive merger agreement to acquire Pittsburgh-base...
Fantastic News!!!
Many across the world have already gotten ICL implanted into their eyes to correct their Myopia.
“Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again.
FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
專欄Top upgrades and downgrades on 3/18
• $好事達(ALL.US)$: Raymond James Upgrades to Strong Buy from Outperform - PT $165 (from $145)
• $DigitalBridge Group(DBRG.US)$: JPMorgan Upgrades to Neutral from Underweight - PT $7
• $佳明(GRMN.US)$: BofA Securities Upgrades to Buy from Neutral - PT $140 (from $165)
• $Guidewire Software(GWRE.US)$: JMP Securities Upgrades to Market Outperform from Market Perform - PT $110
• $MongoDB(MDB.US)$: UBS Upgrades to Buy from Neutral - PT $450 (from $345)...
暫無評論